Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (GB:0JDK)
LSE:0JDK
RESEARCH TOOLSreports
Total Valuation
Iovance Biotherapeutics has a market cap or net worth of $771.39M. The enterprise value is $870.38M.
Market Cap$771.39M
Enterprise Value$870.38M
Share Statistics
Iovance Biotherapeutics has 333,934,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding333,934,400
Owned by Insiders0.30%
Owned by Institutions1.17%
Financial Efficiency
Iovance Biotherapeutics’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -48.98%.
Return on Equity (ROE)-0.52
Return on Assets (ROA)-0.41
Return on Invested Capital (ROIC)-48.98%
Return on Capital Employed (ROCE)-0.50
Revenue Per Employee195.79K
Profits Per Employee-444.13K
Employee Count838
Asset Turnover0.18
Inventory Turnover2.41
Valuation Ratios
The current PE Ratio of Iovance Biotherapeutics is -5.76. Iovance Biotherapeutics’s PEG ratio is -1.02.
PE Ratio-5.76
PS Ratio0.00
PB Ratio11.51
Price to Fair Value3.02
Price to FCF-20.76
Price to Operating Cash Flow-21.66
PEG Ratio-1.02
Income Statement
In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M and earned -372.18M in profits. Earnings per share was -1.28.
Revenue164.07M
Gross Profit40.08M
Operating Income-395.28M
Pretax Income-375.00M
Net Income-372.18M
EBITDA-351.67M
Earnings Per Share (EPS)-1.28
Cash Flow
In the last 12 months, operating cash flow was -334.39M and capital expenditures -13.11M, giving a free cash flow of -347.50M billion.
Operating Cash Flow-334.39M
Free Cash Flow-347.50M
Free Cash Flow per Share-1.04
Dividends & Yields
Iovance Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.72
52-Week Price Change-72.03%
50-Day Moving Average2.58
200-Day Moving Average6.43
Relative Strength Index (RSI)52.26
Average Volume (3m)189.06K
Important Dates
Iovance Biotherapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Iovance Biotherapeutics as a current ratio of 3.74, with Debt / Equity ratio of 3.85%
Current Ratio3.74
Quick Ratio3.31
Debt to Market Cap<0.01
Net Debt to EBITDA0.16
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Iovance Biotherapeutics has paid -2.83M in taxes.
Income Tax-2.83M
Effective Tax Rate<0.01
Enterprise Valuation
Iovance Biotherapeutics EV to EBITDA ratio is -5.94, with an EV/FCF ratio of -5.73.
EV to Sales12.72
EV to EBITDA-5.94
EV to Free Cash Flow-5.73
EV to Operating Cash Flow-5.91
Balance Sheet
Iovance Biotherapeutics has $359.71M in cash and marketable securities with $53.72M in debt, giving a net cash position of -$305.99M billion.
Cash & Marketable Securities$359.71M
Total Debt$53.72M
Net Cash-$305.99M
Net Cash Per Share-$0.92
Tangible Book Value Per Share$1.48
Margins
Gross margin is 0.00%, with operating margin of -240.92%, and net profit margin of -226.84%.
Gross Margin0.00%
Operating Margin-240.92%
Pretax Margin-228.56%
Net Profit Margin-226.84%
EBITDA Margin-214.34%
EBIT Margin-240.92%
Analyst Forecast
The average price target for Iovance Biotherapeutics is $10.73, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.73
Price Target Upside372.69% Upside
Analyst ConsensusModerate Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast―